Product nameAnti-BrdU antibody - Proliferation Marker
See all BrdU primary antibodies
DescriptionSheep polyclonal to BrdU - Proliferation Marker
Tested applicationsSuitable for: IHC-FrFl, IHC-P, IHC-Fr, ICC/IF, ELISA, WB, IHC-FoFrmore details
Species reactivityReacts with: Species independent
Other Immunogen Type corresponding to BrdU. Bromodeoxyuridine coupled to HGG (Human Gamma Globulin)
Unstained positive control slides from mice treated with BrdU (formalin-fixed, paraffin-embedded intestine sections) are available as BrdU control slides ab129956.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.60
Constituent: 0.4% PBS
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab1893 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-FrFl||Use at an assay dependent concentration.|
|IHC-P||Use a concentration of 10 µg/ml.|
|IHC-Fr||Use a concentration of 10 µg/ml.|
|ICC/IF||Use at an assay dependent concentration. PubMed: 21118958|
|ELISA||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration.|
|IHC-FoFr||Use at an assay dependent concentration. PubMed: 19332057|
RelevanceThe immunocytochemical detection of bromodeoxyuridine (BrdU) incorporated into DNA is a powerful tool to study the cytokinetics of normal and neoplastic cells. In vitro or in vivo labeling of tumor cells with the thymidine analogue BrdU and the subsequent detection of incorporated BrdU with specific anti-BrdU monoclonal antibodies is an accurate and comprehensive method to quantitate the degree of DNA-synthesis. BrdU is incorporated into the newly synthezised DNA of S-phase cells may provide an estimate for the fraction of cells in S-phase. Also dynamic proliferative information such as the S-phase transit rate and the potential doubling time can be obtained, by means of bivariate BrdU/DNA flow cytometric analysis.
- Bromodeoxyuridine antibody
- BUdr antibody
Loss of PRC2 results in ectopic formation of Merkel cells around all hair follicle types.
(Panel C) IF staining for BrdU shows no significant change in proliferation in the developing interfollicular epidermis (IFE) and hair follicles (HF) in E16 Ezh1/2 2KO and EED cKO compared to control.
Increased numbers of BrdU-labeled NPCs (neural progenitor cells ) with radial GFAP-positive processes in the DG GCL of CRAF ko at P10.
(Panel A shown) Immunohistological analysis of BrdU (green) and the astrocytic marker GFAP (red) stained sagittal brain sections of CRAF ct and CRAF ko hippocampus at P10 24h after a single BrdU application. Representative brain sections of CRAF ct (upper panel) and CRAF ko (lower panel) show BrdU-labeled cells (green) colocalizing with GFAP-positive radial processes (red) (merge, white arrowheads). Scale bar = 50μm.
ab1893 staining BrdU in COS-7 (African green monkey kidney fibroblast-like cell line) cells by ICC/IF (Immunocytochemistry/immunofluorescence).
Cells were fixed with paraformaldehyde, permeabilized with 0.5% Triton X-100 and blocked with 2% BSA for 1 hour at 25°C. Samples were incubated with primary antibody (1/100 in 2% BSA) for 1 hour at 25°C. ab96945, a DyLight® 594-conjugated rabbit anti-sheep IgG (H+L) polyclonal was used as the secondary antibody (1/200). Nuclei are stained blue with DAPI.
ab1893 staining BrdU in Ramos (Human Burkitt's lymphoma cell line) cell line xenograft tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections).
Tissue was fixed with formaldehyde and blocked with 15% serum for 1 hour at 20°C; antigen retrieval was by heat mediation in a sodium citrate buffer, pH 6. Samples were incubated with primary antibody (1/260 in TBS) for 18 hours at 20°C. An undiluted Alexa Fluor® 488-conjugated donkey anti-sheep IgG polyclonal was used as the secondary antibody.
This product has been referenced in:
- Liang HX et al. Neferine inhibits proliferation, migration and invasion of U251 glioma cells by down-regulation of miR-10b. Biomed Pharmacother 109:1032-1040 (2019). Read more (PubMed: 30551353) »
- Gao W et al. Ailanthone exerts anticancer effect by up-regulating miR-148a expression in MDA-MB-231 breast cancer cells and inhibiting proliferation, migration and invasion. Biomed Pharmacother 109:1062-1069 (2019). Read more (PubMed: 30551356) »